Keeping Track: Label Expansion For AbbVie/J&J's Imbruvica, Theravance's Vibativ
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Keeping Track: Imbruvica Snags First-Line CLL Claim; Gilead TAF Strategy Advances
The latest drug development news and highlights from our FDA Performance Tracker.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.